Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya

Abstract Background The World Health Organisation recommends the use of catch-up campaigns as part of the introduction of pneumococcal conjugate vaccines (PCVs) to accelerate herd protection and hence PCV impact. The value of a catch-up campaign is a trade-off between the costs of vaccinating additi...

Full description

Bibliographic Details
Main Authors: Stefan Flasche, John Ojal, Olivier Le Polain de Waroux, Mark Otiende, Katherine L. O’Brien, Moses Kiti, D. James Nokes, W John Edmunds, J. Anthony G. Scott
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12916-017-0882-9
_version_ 1828852436402438144
author Stefan Flasche
John Ojal
Olivier Le Polain de Waroux
Mark Otiende
Katherine L. O’Brien
Moses Kiti
D. James Nokes
W John Edmunds
J. Anthony G. Scott
author_facet Stefan Flasche
John Ojal
Olivier Le Polain de Waroux
Mark Otiende
Katherine L. O’Brien
Moses Kiti
D. James Nokes
W John Edmunds
J. Anthony G. Scott
author_sort Stefan Flasche
collection DOAJ
description Abstract Background The World Health Organisation recommends the use of catch-up campaigns as part of the introduction of pneumococcal conjugate vaccines (PCVs) to accelerate herd protection and hence PCV impact. The value of a catch-up campaign is a trade-off between the costs of vaccinating additional age groups and the benefit of additional direct and indirect protection. There is a paucity of observational data, particularly from low- and middle-income countries, to quantify the optimal breadth of such catch-up campaigns. Methods In Kilifi, Kenya, PCV10 was introduced in 2011 using the three-dose Expanded Programme on Immunisation infant schedule and a catch-up campaign in children <5 years old. We fitted a transmission dynamic model to detailed local data, including nasopharyngeal carriage and invasive pneumococcal disease (IPD), to infer the marginal impact of the PCV catch-up campaign over hypothetical routine cohort vaccination in that setting and to estimate the likely impact of alternative campaigns and their dose efficiency. Results We estimated that, within 10 years of introduction, the catch-up campaign among children <5 years old prevents an additional 65 (48–84) IPD cases across age groups, compared to PCV cohort introduction alone. Vaccination without any catch-up campaign prevented 155 (121–193) IPD cases and used 1321 (1058–1698) PCV doses per IPD case prevented. In the years after implementation, the PCV programme gradually accrues herd protection, and hence its dose efficiency increases: 10 years after the start of cohort vaccination alone the programme used 910 (732–1184) doses per IPD case averted. We estimated that a two-dose catch-up among children <1 year old uses an additional 910 (732–1184) doses per additional IPD case averted. Furthermore, by extending a single-dose catch-up campaign to children aged 1 to <2 years and subsequently to those aged 2 to <5 years, the campaign uses an additional 412 (296–606) and 543 (403–763) doses per additional IPD case averted. These results were not sensitive to vaccine coverage, serotype competition, the duration of vaccine protection or the relative protection of infants. Conclusions We find that catch-up campaigns are a highly dose-efficient way to accelerate population protection against pneumococcal disease.
first_indexed 2024-12-12T23:53:05Z
format Article
id doaj.art-f0ecf686d1264c84a8db1d5798c69e2b
institution Directory Open Access Journal
issn 1741-7015
language English
last_indexed 2024-12-12T23:53:05Z
publishDate 2017-06-01
publisher BMC
record_format Article
series BMC Medicine
spelling doaj.art-f0ecf686d1264c84a8db1d5798c69e2b2022-12-22T00:06:39ZengBMCBMC Medicine1741-70152017-06-0115111010.1186/s12916-017-0882-9Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, KenyaStefan Flasche0John Ojal1Olivier Le Polain de Waroux2Mark Otiende3Katherine L. O’Brien4Moses Kiti5D. James Nokes6W John Edmunds7J. Anthony G. Scott8Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical MedicineDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical MedicineDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical MedicineKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-CoastInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public HealthKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-CoastKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-CoastDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical MedicineDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical MedicineAbstract Background The World Health Organisation recommends the use of catch-up campaigns as part of the introduction of pneumococcal conjugate vaccines (PCVs) to accelerate herd protection and hence PCV impact. The value of a catch-up campaign is a trade-off between the costs of vaccinating additional age groups and the benefit of additional direct and indirect protection. There is a paucity of observational data, particularly from low- and middle-income countries, to quantify the optimal breadth of such catch-up campaigns. Methods In Kilifi, Kenya, PCV10 was introduced in 2011 using the three-dose Expanded Programme on Immunisation infant schedule and a catch-up campaign in children <5 years old. We fitted a transmission dynamic model to detailed local data, including nasopharyngeal carriage and invasive pneumococcal disease (IPD), to infer the marginal impact of the PCV catch-up campaign over hypothetical routine cohort vaccination in that setting and to estimate the likely impact of alternative campaigns and their dose efficiency. Results We estimated that, within 10 years of introduction, the catch-up campaign among children <5 years old prevents an additional 65 (48–84) IPD cases across age groups, compared to PCV cohort introduction alone. Vaccination without any catch-up campaign prevented 155 (121–193) IPD cases and used 1321 (1058–1698) PCV doses per IPD case prevented. In the years after implementation, the PCV programme gradually accrues herd protection, and hence its dose efficiency increases: 10 years after the start of cohort vaccination alone the programme used 910 (732–1184) doses per IPD case averted. We estimated that a two-dose catch-up among children <1 year old uses an additional 910 (732–1184) doses per additional IPD case averted. Furthermore, by extending a single-dose catch-up campaign to children aged 1 to <2 years and subsequently to those aged 2 to <5 years, the campaign uses an additional 412 (296–606) and 543 (403–763) doses per additional IPD case averted. These results were not sensitive to vaccine coverage, serotype competition, the duration of vaccine protection or the relative protection of infants. Conclusions We find that catch-up campaigns are a highly dose-efficient way to accelerate population protection against pneumococcal disease.http://link.springer.com/article/10.1186/s12916-017-0882-9PneumococcusCatch-upVaccinationPCVDose efficiencyImpact
spellingShingle Stefan Flasche
John Ojal
Olivier Le Polain de Waroux
Mark Otiende
Katherine L. O’Brien
Moses Kiti
D. James Nokes
W John Edmunds
J. Anthony G. Scott
Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
BMC Medicine
Pneumococcus
Catch-up
Vaccination
PCV
Dose efficiency
Impact
title Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
title_full Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
title_fullStr Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
title_full_unstemmed Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
title_short Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
title_sort assessing the efficiency of catch up campaigns for the introduction of pneumococcal conjugate vaccine a modelling study based on data from pcv10 introduction in kilifi kenya
topic Pneumococcus
Catch-up
Vaccination
PCV
Dose efficiency
Impact
url http://link.springer.com/article/10.1186/s12916-017-0882-9
work_keys_str_mv AT stefanflasche assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT johnojal assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT olivierlepolaindewaroux assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT markotiende assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT katherinelobrien assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT moseskiti assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT djamesnokes assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT wjohnedmunds assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya
AT janthonygscott assessingtheefficiencyofcatchupcampaignsfortheintroductionofpneumococcalconjugatevaccineamodellingstudybasedondatafrompcv10introductioninkilifikenya